INTRODUCTION
This update examines and summarizes the most recent data on prevention, testing, and treatment of HIV infection for the general internist. Our aims were: (1) to describe the most recent data on HIV prevention; (2) to discuss the recommendations and emerging evidence for routine HIV screening, particularly in communitybased settings; (3) to interpret the most recent data on initiation and selection of antiretroviral therapy; and (4) to facilitate the application of these findings to the clinical practice of the generalist.
We performed a PUBMED search of from March 2008 through April 2010, using the Medial Subject Heading (MeSH) term "HIV," limited to English language articles focusing on human subjects. Additionally, the authors each reviewed studies published between March 2008 and April 2010 in the major internal medicine and HIV journals. We also performed targeted searches using the search terms "HIV prevention" and "HIV testing." Articles were included after review by consensus among a group of experts, all practicing HIV clinicians and researchers, if they met the following criteria: (1) offered novel findings in HIV prevention, HIV testing, or initiation of antiretroviral therapy; and (2) had the potential for direct clinical relevance to the practicing generalist. We narrowed down our selection by group consensus with the goal of presenting the eight to ten most relevant papers published since March 2008. In HIV-1 infected populations, the seroprevalence of HSV ranges from 60-90% 1 , and studies suggest that HSV may increase HIV transmission. In coinfected cells, HSV proteins bind HIV and promote transcription [2] [3] [4] [5] . HSV reactivation is associated with increased HIV levels in blood and the genital tract, [6] [7] [8] [9] and rates of sexual HIV transmission are markedly higher from persons with genital ulcers. 10 Additionally, several randomized clinical trials (RCTs) demonstrate that anti-HSV therapy decreases plasma HIV levels. 6, [11] [12] [13] [14] This study is an RCT designed to evaluate the effect of daily acyclovir therapy on HIV transmission. 15 The investigators enrolled HIV serodiscordant heterosexual couples from seven sites in southern Africa and seven sites in eastern Africa. For each couple, the HIV-infected partner was seropositive for HSV, had CD4 cell count ≥250 cells/mm 3 , no AIDS-related conditions, no current antiretroviral therapy, and no persistent genital ulcers. The HIV-negative partner was eligible whether HSV-negative or positive. The intervention group received acyclovir 400 mg twice daily, and the control group received an identical-appearing placebo. The primary outcome was HIV incidence. HIV sequencing was used to classify the transmission as 'linked' or 'unlinked.'
There were 3,360 discordant couples included in the final analysis. In 68% of couples, the woman was HIV-infected. More than half of all adults living with HIV/AIDS in subSaharan Africa are women. 21 Most strides that have been made in HIV prevention (condoms, circumcision) depend largely on male cooperation. Topical microbicides offer the possibility of initiation by women. Cellulose sulfate is an entry inhibitor with in-vitro activity against HIV and demonstrated safety and tolerability. This was a randomized, double-blind, placebo-controlled trial 22 of cellulose sulfate gel for prevention of HIV. Women who were 18 or older, had a negative HIV-antibody test and reported three or more acts of vaginal intercourse/ week and three or more different partners in the previous 3 months were recruited from five sites in Africa and India. The intervention group received 6% cellulose sulfate gel and controls an identical placebo (the pH of the compounds were different). The primary outcome was incident HIV infection.
Among 1,398 women, at the prespecified interim analysis point, there were 24 new HIV infections in the cellulose sulfate group and 11 among those receiving placebo (HR: 2.23, 95% CI: 1.05-5.03, p=0.02), prompting early termination of the trial. While this suggested increased risk of HIV transmission among women using cellulose sulfate, the interim analysis did not include an additional six incident cases that had not been entered in the database. Analysis including these cases yielded HR: 1.61 (95 CI: 0.86-3.01, p=0.13). An additional pre-planned analysis censoring data from participants who interrupted cellulose or placebo use (most often due to pregnancy) yielded a HR 2.02 (95% CI 0.97-4.18, p=0.05).
In summary, there was a higher incidence of HIV in the cellulose sulfate group: however, this did not reach significance in the primary effectiveness analysis. It was noted by the investigators that there were non-differential pregnancy rates in the two groups. Given the contraceptive profile of cellulose sulfate, non-adherence might have been a factor in the observed results. This was a multicenter community-based, randomized doubleblind, placebo-controlled trial in Thailand to evaluate the efficacy of vaccines to prevent HIV. 23 The Implementing expanded HIV testing in primary care requires an understanding of the context into which broad testing will be introduced. Bokhour and colleagues conducted focus groups with patients (N=28) and health-care providers (N=13) from primary care clinics at two US Veterans Administration facilities to better understand issues in the expansion of HIV testing. 24 Patients in the four focus groups were HIV-negative men aged 35-88 years, predominantly low income, with a range of educational backgrounds. The two provider focus groups consisted of men (N=6) and women (N=7), and included physicians, nurse practitioners, and a registered nurse.
Semi-structured group interviews led to several recurrent themes. Both patients and health-care providers felt that HIV testing should be routine. Many felt that routine testing could reduce stigma. Concerns were expressed about special written consent forms and the anxieties that they may cause. Though "normalizing" the HIV testing was a consistent theme, results showed that patients wanted to be aware that HIV testing was being done and that it should be explicitly offered, with the option to decline. They also pointed out the need for clear and prompt communication of results.
The Bottom Line: Veteran patients are likely to accept routine testing, but attention to issues of stigma and clear communication about results are important for both patients and providers. To help with patient-centered discussions, the authors developed "Six R's" for routine testing: (1) Raise the topic; (2) Reassure the patient that the offer is routine; (3) provide Rationale for the test; (4) Respond to questions; (5) Request the test; and (6) tell the patient when and how they will get Results.
Arbelaez et al. Emergency Provider Attitudes and Barriers to Universal HIV Testing in the Emergency Department. J Emerg Med. 2009 Oct 13. [Epub ahead of print]
The Centers for Disease Control and Prevention (CDC) HIV testing guidelines include emergency departments (EDs) as target locations for expanded routine HIV testing. 25 This research study surveyed ED providers before and 6 months after institution of an ED-based HIV testing program to understand attitudes toward testing and how they might change with experience. 26 One hundred eight providers (43% nurses, 29% resident physicians, 17% attending physicians, 7% nursing assistants, and 4% physician assistants) completed both pre-and postsurveys. Before starting the HIV testing intervention in the ED, many providers identified barriers to HIV testing such as inadequate resources (70%), inadequate time (51%), and concerns about assuring follow-up (50%). After experience with the intervention, two of these barriers were more frequently reported than at baseline: inadequate time (62%) and follow-up care (59%). In multivariate modeling, female providers, providers who felt they had sufficient time to test, and providers reporting sufficient legal understanding of testing issues were more likely to favor HIV testing in the ED. While most providers favored HIV testing in general (86%), fewer supported doing it in the ED (56%), and still fewer expressed willingness to offer it themselves (37%).
The Bottom Line: For HIV testing in the ED to be substantially adopted, provider perceptions about barriers must be addressed, including concerns about inadequate time and legal ramifications of testing. Federally qualified community health centers (CHC) are a crucial part of the health-care delivery system for predominantly underserved populations. In late 2006 the National Association of Community Health Centers supported the expansion of point-of-care HIV testing programs across North Carolina, South Carolina, and Mississippi. Myers and colleagues conducted a before-and-after analysis of data from six CHCs who adopted routine rapid HIV screening. 27 Efforts included redesign of patient flow, written protocol development, clinic in-service trainings, on-site technical assistance, follow-up support, and dissemination of patient educational materials. During the year prior to program rollout, approximately 3% (N=3,078) of patients seen for care were tested for HIV. During the 13 months after rollout, 16,148 were offered testing, and 10,769 (66%) accepted. Thirty-nine persons tested positive on rapid test results, of whom 20 were confirmed HIV-positive and 17 were new HIV diagnoses. Rates of infection were lower than expected by the investigators, but still higher than thresholds disseminated by the CDC for identifying health-care settings eligible for routine testing. Twelve of the 17 newly diagnosed patients were successfully linked to HIV care. Patients who were white were significantly less likely than African-Americans or Latinos to be HIV tested, as were the oldest patients (those aged 55-64 years). While false positives occurred at rates to be expected for the rapid tests, staff were not fully prepared for false positives, and had to develop procedures for understanding and communicating the inherent uncertainty of the initial, preliminary rapid test results.
The Bottom Line: Routine point of care testing markedly increased screening rates in community health centers. Table 1 When to start antiretroviral therapy (ART) has been an ongoing controversy. 29, 30 The decision regarding when to start therapy has to balance anticipated benefits with potential side effects, impact on quality of life, and risk of therapeutic burnout and virologic resistance. Potential benefits of starting early include: modulation of the inflammatory response, lowering of the viral set point, higher rates of immune reconstitution, and use of treatment as prevention. 31, 32 Kitahata, writing for the NA-ACCORD investigators, investigated the effects of starting therapy at different levels of CD4 counts 33 . , and it is unclear why there is a discrepancy at this higher range. Even larger differences were seen for comparisons with lower CD4 counts at time of treatment initiation.
WHAT TO START IN ANTIRETROVIRAL NAÏVE PATIENTS
Because both of these studies are based on observational cohort data, the potential for unmeasured confounders exists. ART initiation is no doubt strongly associated with health status, physician expectations, and patient health seeking behaviors. Both studies adjusted for or excluded patients with a history of injection drug use as a major potential confounder. The NA-ACCORD investigators performed a sensitivity analysis that found a large confounder effect would be needed to reduce or negate their findings. However, an effect of this magnitude was uncovered by the Women's Health Initiative trial of hormone replacement therapy in primary prevention of coronary heart disease compared to prior observational cohort studies. 35 An RCTof ART, the Strategic . Increased adoption of routine testing may identify those with HIV at earlier CD4 counts.
